Advancements in BioNeMo Platform

The life sciences industry generates vast amounts of data, and NVIDIA's BioNeMo platform is designed to turn this data into actionable insights. This will not only enhance discovery but also significantly reduce research and development costs, which currently stand at an estimated $300 billion annually. Key expansions in the BioNeMo platform include:

• NVIDIA Clara™ open models: Introducing the RNAPro model for RNA structure prediction and the ReaSyn v2 model for practical AI drug synthesis.
• BioNeMo Recipes: Streamlining and scaling biological foundation model training and deployment.
• Data Processing Libraries: Including nvMolKit, a GPU-accelerated cheminformatics tool for molecular design.

“Biology and drug discovery are reaching their transformer moments,” stated Kimberly Powell, Vice President of Healthcare at NVIDIA. “BioNeMo turns experimental data into usable intelligence for AI, creating a continuous learning cycle that speeds up discovery.”

Partnership with Eli Lilly

Eli Lilly announced a groundbreaking collaboration with NVIDIA to establish a co-innovation lab, targeting some of the most persistent challenges in drug discovery. This partnership integrates NVIDIA's strength in accelerated computing and AI with Lilly's extensive experience in drug development.

"We see this as a catalyst for capabilities that will define the next era of drug discovery," remarked Diogo Rau, Executive Vice President and Chief Information and Digital Officer at Lilly. The collaboration aims not only to advance drug discovery but to enhance operations across Lilly’s entire business spectrum, from manufacturing to commercial activities.

Thermo Fisher’s Collaboration with NVIDIA

NVIDIA is also joining forces with Thermo Fisher to create an autonomous lab infrastructure intended to enhance scientific discovery efficiency. This partnership will transform research laboratories into scalable, automated centers for data generation, focusing on:

• Unified Edge-to-Cloud AI Compute: Leveraging NVIDIA DGX Spark™ supercomputers for seamless lab workflows.
• Multi-Agent Systems: Utilizing the NVIDIA NeMo™ suite to enable autonomous experiment orchestration.
• Autonomous Data Analysis: Incorporating BioNeMo tools for real-time data interpretation, accelerating the process from raw data to scientific insight.

Gianluca Pettitti, Executive Vice President at Thermo Fisher Scientific, expressed that “Artificial intelligence coupled with laboratory automation will transform how scientific work is performed,” underlining the collaborative aim to accelerate impactful discoveries.

Global Ecosystem Building on BioNeMo

Innovators worldwide are now leveraging NVIDIA's BioNeMo platform to advance drug discovery. Companies such as Basecamp Research and Natera are integrating AI to enhance the drug design process significantly. Highlights include:

• Basecamp Research: Developed the EDEN family of AI models for precise genetic medicine applications.
• Natera: Launched an AI foundation model platform rooted in extensive genomic datasets.

The landscape is further enriched by emerging AI scientists employing NVIDIA's frameworks to establish digital labs for scientific exploration.